ABC News’ Rebecca Jarvis looks at artificial intelligence’s role in the medical field and how it’s allowing doctors to expand their research and make decisions

We talk with a doctor who discovered a cure for rare diseases with the help of artificial intelligence. Share this

Every Cure was excited to announce our 3 year, 48.3M contract with ARPA-H at the White House! The ARPA-H contract is aimed to develop our

A nonprofit that seeks to repurpose approved drugs for new indications will receive more than $48 million from the U.S. Advanced Research Projects Agency for

Over the past few years, Every Cure has developed a blueprint for an AI-powered platform that can do what humans can’t — match thousands of

Every Cure, cofounded by Penn’s David Fajgenbaum, received a three-year $48 million federal contract to develop an AI tool for rare diseases. Share this

Agency backs non-profit’s agnostic approach to drug repurposing with $48.3M Share this

ABC News chief medical correspondent Dr. Jen Ashton discusses Every Cure’s AI platform that aims to match FDA-approved drugs with diseases currently lacking approved treatments.

On this Rare Disease Day, we are highlighting Madison, a patient diagnosed with a rare form of leukodystrophy (LBSL) who is fighting for her ability

The White House is hoping to use AI to match already approved drugs with untreated diseases. The federal government is giving nonprofit Every Cure nearly

New database aims to match rare-disease patients with drugs on pharmacy shelves Share this

ARPA-H contract will supercharge Every Cure’s work to identify existing medicines that can be repurposed to treat currently untreated diseases. Initial progress utilizing a pilot

The three-year, $48.3 million ARPA-H contract will supercharge Every Cure’s work to identify existing medicines that can be repurposed to treat currently untreated diseases. Share

Winning startups join more than 20 companies at New York City’s cutting-edge healthcare innovation campus Share this

Dr. David Fajgenbaum saved his own life by tracking down a generic drug that cured his rare and deadly disease. Now with nonprofit Every Cure,

David Fajgenbaum discovered a repurposed drug to save his own life and is now on a mission with Every Cure Co-Founders Grant Mitchell and Tracey

Every Cure is a non-profit, founded by Dr. David Fajgenbaum following his brush with a near-fatal rare disease that doctors struggled to diagnose, that finds new uses for

New Partnership Enables Real World Data Confirmation of Drug Repurposing Opportunities and Trial Emulation Capabilities to Speed Clinical Development Share this

This Challenge is a bold initiative to incubate innovations by healthcare start-ups and entrepreneurs across disciplines and sectors to responsibly and equitably use artificial intelligence

AI has also enabled the discovery of a new application for an existing drug in treating a rare disease, iMCD. This development represents a significant breakthrough,